Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Duchenne Muscular Dystrophy Treatable with Modified Gene Engineering Therapy

By BiotechDaily International staff writers
Posted on 17 Jun 2013
Image: The TALEN finds its target site in the human genome by binding to DNA, shown in green, with an engineered DNA-recognition protein, shown in orange. Once the protein finds its target site, the DNA is modified by the enzyme domain of the protein shown in blue (Photo courtesy of Dr. Charles Gersbach, Duke University).
Image: The TALEN finds its target site in the human genome by binding to DNA, shown in green, with an engineered DNA-recognition protein, shown in orange. Once the protein finds its target site, the DNA is modified by the enzyme domain of the protein shown in blue (Photo courtesy of Dr. Charles Gersbach, Duke University).
A team of biomedical engineers has demonstrated the potential for curing Duchenne muscular dystrophy (DMD) with modified gene editing therapy that does not require a DNA repair template.

DMD is caused by mutations in the gene that encodes the protein dystrophin and the subsequent disruption of the dystrophin-associated protein complex (DAPC). The mutation occurs on the X-chromosome, and the disease effects about one of every 3,500 boys whose muscle function is so degraded that they die usually before reaching the age of 30.

Having based their experiments on the premise that many genetic diseases could be treated simply by correcting a disrupted DNA reading frame, investigators at Duke University (Durham, NC, USA) recently reported that genome editing with transcription activator-like effector nucleases (TALENs), without a repair template, could efficiently correct the reading frame and restore the expression of a functional dystrophin protein.

Restriction enzymes are enzymes that cut DNA strands at a specific sequence. TALENs can be engineered to bind practically any desired DNA sequence, and by combining such an engineered TALEN with a DNA cleavage domain (which cuts DNA strands), one is able to engineer restriction enzymes that are specific for any desired DNA sequence. When these restriction enzymes are introduced into cells, they can be used for genome editing in situ, a technique known as genome editing with engineered nucleases.

The Duke University investigators engineered a TALEN gene to mediate highly efficient gene editing at exon 51 of the dystrophin gene. The gene was inserted into plasmids, and the plasmids were used to transfect target cells including skeletal myoblasts and dermal fibroblasts. The TALENs were then used to edit the genome by inducing double-strand breaks (DSB), to which the cells responded with repair mechanisms.

Results published in the June 4, 2013, online edition of the journal Molecular Therapy revealed that genome editing with TALENs, but without a repair template, could efficiently correct the reading frame and restore the expression of functional dystrophin protein that had been mutated in DMD.

"Conventional genetic approaches to treating the disease involve adding normal genes to compensate for the mutated genes," said senior author Dr. Charles Gersbach, assistant professor of biomedical engineering at Duke University. "However, this can cause other unforeseen problems, or the beneficial effect does not always last very long. Our approach actually repairs the faulty gene, which is a lot simpler. It finds the faulty gene and fixes it so it can start producing a functional protein again."

"Similar approaches could be helpful in treating other genetic diseases where a few gene mutations are responsible, such as sickle cell disease, hemophilia, or other muscular dystrophies," said Dr. Gersbach.

Related Links:
Duke University



Channels

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.